Darmstadt, Germany -– Merck today announced that the Board of

Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice

Chairman of the Executive Board. Concurrently, Belén Garijo (54) was appointed to the

Executive Board to take over leadership for the Pharma business. The management

changes will become effective as of January 1, 2015.

Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chairman of the

Executive Board. Both will share strategic management functions and will represent the

company with politicians and international organizations.

As a member of the Executive Board, Garijo, currently CEO of Merck’s

biopharmaceutical division Merck Serono, will take on responsibility for the whole

Pharma business. Besides Merck Serono, this includes Consumer Health, Allergy and

Biosimilars.

“With today’s management decisions we strengthen Merck’s leadership team and

prepare the ground for continuity to reach our ambitious growth targets until the year

2018 and beyond,” said Johannes Baillou, Chairman of the Board of Partners of

E. Merck KG. “Stefan Oschmann who has successfully reorganized our pharma News Release

businesses over the past years will familiarize himself with Group-wide functions and

will increasingly assume external responsibilities for the company. Belén Garijo has

many years of experience in the pharma industry, has proven that she can further

develop our business organization and in her future role will provide a significant

contribution to ensure the sustainable success of our pharma businesses.”